Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co | Buenos Aires | Healthcare | Pharmaceuticals | ARS 809.02T | 112.4x | 8.72 | ARS 19,600 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson & Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 389.03T | 27x | 0.11 | ARS 13,150 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 389.03T | 27x | ARS 1,600 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Johnson & Johnson | Buenos Aires | Healthcare | Pharmaceuticals | ARS 378.84T | 10.4x | 0.31 | ARS 815 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Abbvie | Buenos Aires | Healthcare | Pharmaceuticals | ARS 327.86T | 62.8x | -1.68 | ARS 22,550 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck & Co DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 270.92T | 20.1x | 0.06 | ARS 25,975 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 236.66T | 37.4x | 8.67 | ARS 46,650 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 231.92T | 14.8x | 0.2 | ARS 34,850 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen | Buenos Aires | Healthcare | Pharmaceuticals | ARS 169.38T | 55.1x | -0.92 | ARS 12,850 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 162.17T | -63.6x | 0.57 | ARS 8,730 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences | Buenos Aires | Healthcare | Pharmaceuticals | ARS 105.91T | 102.8x | -1.24 | ARS 25,900 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol-Myers Squibb DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 105.58T | -16.5x | 0.09 | ARS 21,150 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | Buenos Aires | Healthcare | Pharmaceuticals | ARS 76.74T | 14.8x | -0.2 | ARS 11,600 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen AR | Buenos Aires | Healthcare | Pharmaceuticals | ARS 27.18T | 23.9x | -0.42 | ARS 17,575 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | Buenos Aires | Healthcare | Pharmaceuticals | ARS 26.62T | 32.3x | 0.18 | ARS 44,700 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Laboratorios Richmond | Buenos Aires | Healthcare | Pharmaceuticals | ARS 75.91B | 21.4x | 0.12 | ARS 940 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Instituto Rosenbusch | Buenos Aires | Healthcare | Pharmaceuticals | ARS 4.02B | 4x | 0.01 | ARS 94.50 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |